Wanbury Limited has informed the Exchange regarding a press release dated August 06, 2025, titled "Press Release on Q1 26 Unaudited Financial Results".
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 3.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wanbury Limited reported its Q1 FY26 consolidated results with revenue from operations at ₹163.2 crore, up 24% year-on-year from ₹131.1 crore in Q1 FY25. EBITDA (including other income) surged 108% YoY to ₹24.8 crore, with EBITDA margin expanding by 610 basis points to 15.2%. Profit after tax jumped to ₹13.5 crore from just ₹1.0 crore in Q1 FY25 — a 1,198% YoY increase — taking PAT margin to 8.3%. On a quarter-on-quarter basis, however, revenue declined 5%, EBITDA fell 21%, and PAT dropped 33% compared to Q4 FY25. Key business updates include the pan-India launch of C R ED RED (an anemia management product), GMP certification of its Patalganga and Tanuku API plants from Brazil's ANVISA, and a Board-approved ₹85 crore CAPEX plan for new APIs.
The sharp YoY jump in PAT and margin expansion signal a strong recovery year for Wanbury, though the QoQ moderation may temper near-term enthusiasm. Shareholders can view the new product launches, regulatory wins, and CAPEX approval as positive growth catalysts, while limited US exposure (~15% of exports) provides some insulation from tariff risks.